Recruitment

Recruitment Status
Completed
Estimated Enrollment
318

Inclusion Criteria

The subject and/or their caregiver is physically able and willing to apply the Investigational Product at home.
Has active head lice infestation at Screening as determined by a trained evaluator with the exception of the male head of household who may self-assess as being lice-free. Active head lice infestation is defined as at least three live lice for the index subject and at least one live louse for the other household members.
Has signed an informed consent and/or assent form.
...
The subject and/or their caregiver is physically able and willing to apply the Investigational Product at home.
Has active head lice infestation at Screening as determined by a trained evaluator with the exception of the male head of household who may self-assess as being lice-free. Active head lice infestation is defined as at least three live lice for the index subject and at least one live louse for the other household members.
Has signed an informed consent and/or assent form.
Male or female, aged six months of age or older.
Agrees to an examination for head lice and to all visits and procedures throughout the study.
Is in good general health based on medical history.
Belongs to a household with an eligible index subject with active head lice infestation.

Exclusion Criteria

Has a condition that, in the opinion of the Investigator, may increase the risk to the subject and/or the interpretation of the data.
Has visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or Sponsor, will interfere with safety and/or efficacy evaluations.
Had treatment (over-the-counter ), home remedy or prescription medication) for head lice within 14 days prior to Day 0.
...
Has a condition that, in the opinion of the Investigator, may increase the risk to the subject and/or the interpretation of the data.
Has visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or Sponsor, will interfere with safety and/or efficacy evaluations.
Had treatment (over-the-counter ), home remedy or prescription medication) for head lice within 14 days prior to Day 0.
Has eczema or atopic dermatitis of skin/scalp.
Intends to use any other form of lice treatment from Day 0 through the Day 14 visit, unless provided as rescue therapy to this Protocol.
Has received an investigational agent within 30 days prior to Day 0.
Receiving systemic or topical medication, which in the opinion of the Investigator, may compromise the integrity of the safety and/or efficacy assessments.
Has had a prior reaction to Nix® or products containing permethrin.
Intends to use a lice comb from the Day 0 through the Day 14 visit unless provided as rescue therapy to this Protocol.
Has a household member(s) who is infested with lice but is not willing or not eligible for enrollment.
Does not have a known household affiliation with the household members (i.e., does not stay in one household consistently, or sleeps at one place for several nights and then at another place or location).
Intends to cut their hair, use hair dye/bleach or have permanent wave hairstyling from Day 0 through the Day 14 visit.

Summary

Conditions
Head Lice Infestation
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 6 years and 125 years
Gender
Both males and females

Description

This was a randomized, double-blind, multicenter, vehicle-controlled, parallel-group study in subjects with active head lice infestation. The study was designed to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when ...

This was a randomized, double-blind, multicenter, vehicle-controlled, parallel-group study in subjects with active head lice infestation. The study was designed to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to scalp and hair for 10 minutes at home. Approximately 106 index subjects with their household members were enrolled into the study. A total of approximately 318 subjects were enrolled, assuming an average of 3 members per household participating in the study.

Inclusion Criteria

The subject and/or their caregiver is physically able and willing to apply the Investigational Product at home.
Has active head lice infestation at Screening as determined by a trained evaluator with the exception of the male head of household who may self-assess as being lice-free. Active head lice infestation is defined as at least three live lice for the index subject and at least one live louse for the other household members.
Has signed an informed consent and/or assent form.
...
The subject and/or their caregiver is physically able and willing to apply the Investigational Product at home.
Has active head lice infestation at Screening as determined by a trained evaluator with the exception of the male head of household who may self-assess as being lice-free. Active head lice infestation is defined as at least three live lice for the index subject and at least one live louse for the other household members.
Has signed an informed consent and/or assent form.
Male or female, aged six months of age or older.
Agrees to an examination for head lice and to all visits and procedures throughout the study.
Is in good general health based on medical history.
Belongs to a household with an eligible index subject with active head lice infestation.

Exclusion Criteria

Has a condition that, in the opinion of the Investigator, may increase the risk to the subject and/or the interpretation of the data.
Has visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or Sponsor, will interfere with safety and/or efficacy evaluations.
Had treatment (over-the-counter ), home remedy or prescription medication) for head lice within 14 days prior to Day 0.
...
Has a condition that, in the opinion of the Investigator, may increase the risk to the subject and/or the interpretation of the data.
Has visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or Sponsor, will interfere with safety and/or efficacy evaluations.
Had treatment (over-the-counter ), home remedy or prescription medication) for head lice within 14 days prior to Day 0.
Has eczema or atopic dermatitis of skin/scalp.
Intends to use any other form of lice treatment from Day 0 through the Day 14 visit, unless provided as rescue therapy to this Protocol.
Has received an investigational agent within 30 days prior to Day 0.
Receiving systemic or topical medication, which in the opinion of the Investigator, may compromise the integrity of the safety and/or efficacy assessments.
Has had a prior reaction to Nix® or products containing permethrin.
Intends to use a lice comb from the Day 0 through the Day 14 visit unless provided as rescue therapy to this Protocol.
Has a household member(s) who is infested with lice but is not willing or not eligible for enrollment.
Does not have a known household affiliation with the household members (i.e., does not stay in one household consistently, or sleeps at one place for several nights and then at another place or location).
Intends to cut their hair, use hair dye/bleach or have permanent wave hairstyling from Day 0 through the Day 14 visit.

Tracking Information

NCT #
NCT02060903
Collaborators
  • Accelovance
  • Syneos Health
Investigators
Study Director: Srinivas Sidgiddi, MD Dr. Reddy's Laboratories Inc.
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024